RT Journal Article
SR Electronic
T1 Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.16.22275163
DO 10.1101/2022.05.16.22275163
A1 Kenny, Grace
A1 Negi, Riya
A1 O’Reilly, Sophie
A1 Garcia-Leon, Alejandro
A1 Alalwan, Dana
A1 Gaillard, Colette Marie
A1 Saini, Gurvin
A1 Inzitari, Rosana
A1 Feeney, Eoin R.
A1 Yousif, Obada
A1 Cotter, Aoife
A1 de Barra, Eoghan
A1 Sadlier, Corinna
A1 Crispie, Fiona
A1 Doran, Peter
A1 Gautier, Virginie
A1 Mallon, Patrick WG
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/05/17/2022.05.16.22275163.abstract
AB Measurement of quantitative antibody responses are increasingly important in evaluating the immune response to infection and vaccination. In this study we describe the validation of a quantitative, multiplex serologic assay utilising an electrochemiluminescence platform, which measures IgG against the receptor binding domain (RBD), spike S1 and S2 subunits and nucleocapsid antigens of SARS-CoV-2. The assay displayed a sensitivity ranging from 73-91% and specificity from 90 to 96% in detecting previous infection with SARS-CoV-2 depending on antigenic target and time since infection, and this assay highly correlated with commercially available assays. The within-plate coefficient of variation ranged from 3.8-3.9% and the inter-plate coefficient of variation from 11-13% for each antigen.Competing Interest StatementEoin Feeney has received consulting fees from Gilead, ViiV and Vidacare Ireland. Eoghan de Barra has received consulting fees from Sanofi Pasteur and honoraria/travel grant from Pfizer. Patrick Mallon has received honoraria and/or travel grants from Gilead Sciences, MSD, Bristol Myers Squibb, and ViiV Healthcare.Funding StatementThis work was supported by Science Foundation Ireland (grant numbers 20/COV/0305 and 20/COV/8549) and a philanthropic donation from Smurfit Kappa and the VACCELERATE the European Corona Vaccine Trial Accelerator Platform. GK is funded through a fellowship from the United States Embassy in Ireland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Office of the National Research Ethics Committee Ireland St. Vincents Healthcare Group, Ethics and Medical Research Committee and the Mater Misericordiae University Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to pseudonymised data can be requested by submission to the All Ireland Infectious Diseases Cohort steering group, access will be granted depending on a data protection impact assessment and assessment of the research proposal.